Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division
Avacta Group, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today […]
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment
CANbridge Pharmaceuticals, a global biopharmaceutical company, with a foundation in China, committed to the research, […]
Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates
Salubris Biotherapeutics, a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, […]
Phase III RUBY Clinical Trial Shows Jemperli Could Redefine Cancer Treatment
GSK today announced interim results from Part 1 of the RUBY/ENGOT-EN-6-NSGO/GOG3031 phase III trial investigating […]
Fujitsu launches Cloud-based Platform for Healthcare in Japan
Fujitsu today announced the launch of a new cloud-based platform that allows users to securely […]
OncoVerity Announces Exclusive Worldwide Licensing Rights to Cusatuzumab
OncoVerity, a pioneer in applying advanced multiomic, data driven patient stratification to the development of […]
Cora Therapeutics Announces $1M in Seed Funding
Cora Therapeutics, a Toronto-based life sciences start-up, is pleased to announce the company has raised […]
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
Aadi Bioscience, a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined […]
NHS Slashes Longest Elective and Cancer Patient Waiting Lists
The number of people waiting over 18 months for NHS care has fallen again despite […]
NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced it has signed […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more